Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 02 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Jul 2016 Status changed from recruiting to active, no longer recruiting.